Hepatitis B testing can show whether you have a current or past HBV infection and whether you have antibodies from a hepatitis B vaccine. Hepatitis B is a viral infection caused by the hepatitis B ...

In a recent meta-analysis of patients with resolved hepatitis B who underwent chemotherapy for hematological malignancies, the presence of positive antibodies to HBV surface antigen, or anti-HBs, was ...

Hepatitis B immunoglobulin (HBIG) is important in the management of hepatitis B virus (HBV) infection. Aiming to develop recombinant monoclonal antibodies as an alternative to HBIG, we report the ...

Hepatitis B screening and positivity prior to chemotherapy. Background: Reactivation of hepatitis B virus (HBV) infection is a well-recognized complication after immunosuppressive therapy and can lead ...

Hepatitis B is a viral infection that impacts the liver. To test for hepatitis B, a doctor can perform a blood test that detects hepatitis B surface antigens. A positive result indicates a hepatitis B ...

A robust anamnestic response was mounted in most adolescents when challenged with a dose of monovalent HBV vaccine. More than half of the adolescents who received a 4-dose vaccination schedule in ...

Hepatitis B vaccine is effective in preventing infection with hepatitis B virus (HBV), but its duration of protection is unknown. To examine the effect of exposure to HBV on an immunized population, ...

A combination treatment involving tobevibart and elebsiran significantly improved disease activity in adults with chronic ...

K. Neriishi, S. Akiba, T. Amano, T. Ogino and K. Kodama On the basis of previous studies showing an association between hepatitis B surface antigen (HBsAg) positivity and radiation exposure in atomic ...

Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical ...

WARMINSTER, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), announced today its decision to discontinue AB-452, its first generation orally available hepatitis B ...